May 5, 2026
Carlsbad, California, May 5, 2026 — Rapalogix Health, a biotechnology company advancing a science-first approach to cellular longevity and skin health, today announced the appointment of Thomas Christenson as Chief Financial Officer. Tom brings more than 30 years of financial leadership experience across the professional skincare and life sciences industries, with a proven track record of scaling high-growth companies and executing transactions that deliver strong outcomes for investors.
As CFO, Tom will oversee Rapalogix Health’s financial strategy, capital planning, and corporate development activities as the company advances RLX-201, its proprietary pro-longevity molecule, and Re-Q Pro-Longevity Face Serum, the first product from its professional skincare brand, Re-Q Health. His responsibilities will span financial planning and analysis, accounting and reporting, investor relations, and the operational infrastructure required to support the company's next phase of growth. He will also play a central role in financing strategy, business development, and partnerships as the company expands its pipeline.
Tom joins Rapalogix from his independent financial consulting practice, where he has provided senior-level financial and fractional CFO services to companies in the skincare and aesthetics industries, including The Carol Cole Company (NuFace), where he currently serves on the Board of Directors. He previously served as Chief Financial Officer of Alastin Skincare, Inc. from 2016 to 2024, where under his financial leadership, Alastin grew from $2 million in sales in 2016 to over $100 million in 2023 and earned recognition on the Kline Report, Inc. 5000, Deloitte Technology Fast 500, and Forbes Best Startup lists, along with the San Diego Top Workplaces 2021 Award. He raised $33 million in equity, secured a $10 million venture debt facility, and was a key member of the executive team that negotiated Alastin’s sale to Galderma in December 2021, followed by successful integration of the businesses.
Earlier in his career, Tom held senior finance roles at a variety of life sciences companies including Zogenix, Inc., SkinMedica, Inc., and Diversa Corporation, with experience spanning IPOs, follow-on equity financings, venture debt, royalty interest financings, M&A, and commercial product launches. He holds an MBA in Finance from the University of Illinois, Urbana-Champaign, and a BA in Economics from the University of California, Irvine.
“Tom brings the kind of financial leadership we need at this stage of our growth,” said Rahul Mehta, PhD, CEO and Co-Founder of Rapalogix Health. “He has scaled some of the most respected companies in professional skincare, and his experience navigating financings and transactions in our industry will be instrumental as we advance RLX-201 and expand Re-Q Health.”
Tom’s appointment comes on the heels of a significant period of recognition for Rapalogix Health, including First Place, Start-Up of the Year at the IMCAS Innovation Tank 2026 in Paris; the Judges’ Choice Award at Octane’s 7th Annual Aesthetics Tech Forum; and the 2026 Beauty & Longevity CHOICE Awards for Start-Up of the Year and Cellular Signaling & Advanced Longevity Mechanisms at the INNOCOS Beauty, Tech & Longevity Summit. Together with the recent appointment of Angela Hildebrand as Chief Commercial Officer, who is actively expanding the company's sales team, these additions reflect a broader period of growth for Rapalogix Health as it scales RLX-201 and the Re-Q Health brand across professional skincare channels.
About Rapalogix Health
Rapalogix Health is a California-based biotechnology company pioneering the next evolution in skin health. We translate foundational insights in longevity science into transformative dermatological solutions. Grounded in a science-first approach, the company is developing an innovative pipeline of prescription therapeutics and professional skincare products. Re-Q Pro-Longevity Face Serum, the first product from Rapalogix’s professional skincare brand, Re-Q Health, is now available at select dermatology practices in the United States. Re-Q Pro-Longevity Face Serum is powered by RLX-201, Rapalogix’s proprietary pro-longevity molecule designed to reset and restore exhausted skin cells, extend their longevity, and deliver healthy and youthful skin over a lifetime.
For more information on Rapalogix Health, visit www.rapalogix.com or follow Rapalogix on LinkedIn and Instagram.
For more information on Re-Q Health, visit www.reqhealth.com or follow Re-Q Health on Instagram.
